UY39468A - Materiales y métodos biosintéticos para el biotransporte multidireccional - Google Patents

Materiales y métodos biosintéticos para el biotransporte multidireccional

Info

Publication number
UY39468A
UY39468A UY0001039468A UY39468A UY39468A UY 39468 A UY39468 A UY 39468A UY 0001039468 A UY0001039468 A UY 0001039468A UY 39468 A UY39468 A UY 39468A UY 39468 A UY39468 A UY 39468A
Authority
UY
Uruguay
Prior art keywords
pigr
single domain
domain antibodies
biotransport
multidirectional
Prior art date
Application number
UY0001039468A
Other languages
English (en)
Inventor
Ninkka Tamot
B Harvilla Paul
Jack Borrok Martin Iii
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY39468A publication Critical patent/UY39468A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos de dominio único que se unen al pIgR. Los anticuerpos de dominio único pueden competir con la unión de la IgA al pIgR, o alternativamente, los anticuerpos de dominio único puede competir con la unión de la IgA al pIgR. Los anticuerpos de dominio único pueden acoplarse a agentes terapéuticos para facilitar el suministro del agente terapéutico a la capa de la mucosa a través de transcitosis mediada por el pIgR. El agente terapéutico puede ser, p. ej., una molécula pequeña o una molécula grande tal como un anticuerpo
UY0001039468A 2020-10-12 2021-10-12 Materiales y métodos biosintéticos para el biotransporte multidireccional UY39468A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063090651P 2020-10-12 2020-10-12
US202063090654P 2020-10-12 2020-10-12
US202063090647P 2020-10-12 2020-10-12

Publications (1)

Publication Number Publication Date
UY39468A true UY39468A (es) 2022-04-29

Family

ID=81078722

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039468A UY39468A (es) 2020-10-12 2021-10-12 Materiales y métodos biosintéticos para el biotransporte multidireccional

Country Status (5)

Country Link
US (1) US20220112276A1 (es)
EP (1) EP4225798A1 (es)
TW (1) TW202229335A (es)
UY (1) UY39468A (es)
WO (1) WO2022081460A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02009449A (es) * 2000-03-27 2003-09-22 Univ California Ligandos dirigidos a la region no del eje del componente no secretor de la pigr y metodos de uso de los mismos.
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
US9213029B2 (en) * 2013-06-25 2015-12-15 Samsung Electronics Co., Ltd. Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients
US20220144970A1 (en) * 2019-03-29 2022-05-12 University Of Massachusetts ANTI-POLYMERIC IgA ANTIBODIES AND METHODS OF USE

Also Published As

Publication number Publication date
EP4225798A1 (en) 2023-08-16
TW202229335A (zh) 2022-08-01
WO2022081460A1 (en) 2022-04-21
US20220112276A1 (en) 2022-04-14
WO2022081460A8 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
CO2020016559A2 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
CL2016000376A1 (es) Anticuerpos anti-prlr y sus usos
CO2021016552A2 (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
AR128047A2 (es) Moléculas de anticuerpos que se unen a il-17a e il-17f
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
PE20210375A1 (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
MX2020004381A (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
UY39468A (es) Materiales y métodos biosintéticos para el biotransporte multidireccional
AR122546A1 (es) Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
PE20221326A1 (es) Anticuerpos anti-mertk y metodos de uso de los mismos
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
CL2020000977A1 (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos.
CL2018000131A1 (es) Inmunoconjugados de il22
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
CO2023017609A2 (es) Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
PE20221459A1 (es) Conjugados anticuerpo-farmaco dirigido a claudina 18.2
CL2023001800A1 (es) Conjugados anticuerpo-fármaco específicos para tumores con claudina 18.2
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
PE20161413A1 (es) Conjugados de anticuerpo anti-efna4-farmaco
ECSP22014913A (es) Materiales y métodos para el direccionamiento al receptor de anticuerpos poliméricos
AR115571A1 (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas